NDC-11 (Package) | NDC-9 (Product) | Generic Name | Brand Name | Strength (Ascending) | SEER*Rx Category | Major Class | Minor Class | Administration Route | Package Effective Date | Package Discontinuation Date | Status |
---|---|---|---|---|---|---|---|---|---|---|---|
00054-8604-25 | 00054-8604 | Megestrol Acetate | Megestrol Acetate | 40.0 mg/1 | Hormonal Therapy | Progestin Analog | Oral | Sept. 29, 1995 | Jan. 31, 2019 | No Longer Used | |
00615-3570-31 | 00615-3570 | Megestrol Acetate | Megestrol Acetate | 40.0 mg/1 | Hormonal Therapy | Progestin Analog | Oral | Aug. 8, 1988 | In Use | ||
00615-3570-39 | 00615-3570 | Megestrol Acetate | Megestrol Acetate | 40.0 mg/1 | Hormonal Therapy | Progestin Analog | Oral | Aug. 8, 1988 | In Use | ||
53808-0614-01 | 53808-0614 | Megestrol Acetate | Megestrol Acetate | 40.0 mg/1 | Hormonal Therapy | Progestin Analog | Oral | July 1, 2009 | In Use | ||
63739-0165-10 | 63739-0165 | Megestrol Acetate | Megestrol Acetate | 40.0 mg/1 | Hormonal Therapy | Progestin Analog | Oral | Aug. 8, 1988 | July 31, 2021 | No Longer Used | |
69189-0608-01 | 69189-0608 | Megestrol Acetate | Megestrol Acetate | 40.0 mg/1 | Hormonal Therapy | Progestin Analog | Oral | March 2, 2015 | May 24, 2017 | No Longer Used | |
49349-0946-41 | 49349-0946 | Triamcinolone Acetonide | Kenalog-40 | 40.0 mg/1 | Hormonal Therapy | Adrenal Glucocorticoid | Corticosteroid | Intramuscular | April 11, 2013 | April 19, 2017 | No Longer Used |
49349-0947-41 | 49349-0947 | Triamcinolone Acetonide | Kenalog-40 | 40.0 mg/1 | Hormonal Therapy | Adrenal Glucocorticoid | Corticosteroid | Intramuscular | April 11, 2013 | April 11, 2014 | No Longer Used |
00591-2436-15 | 00591-2436 | Isotretinoin | Isotretinoin | 40.0 mg/1 | Hormonal Therapy | Immunomodulator | Retinoic Acid Derivative | Oral | April 29, 2021 | In Use | |
00006-0464-01 | 00006-0464 | Aprepitant | Emend | 40.0 mg/1 | Ancillary Therapy | Antiemetic | Substance P/Neurokinin 1 | Oral | March 26, 2003 | In Use | |
00006-0464-05 | 00006-0464 | Aprepitant | Emend | 40.0 mg/1 | Ancillary Therapy | Antiemetic | Substance P/Neurokinin 1 | Oral | March 26, 2003 | Dec. 31, 2020 | In Use |
00006-0464-10 | 00006-0464 | Aprepitant | Emend | 40.0 mg/1 | Ancillary Therapy | Antiemetic | Substance P/Neurokinin 1 | Oral | March 26, 2003 | Dec. 31, 2020 | In Use |
72237-0102-02 | 72237-0102 | selinexor | XPOVIO | 40.0 mg/1 | Chemotherapy | Enzyme Inhibitor | XPO1 | Oral | May 19, 2021 | In Use | |
72237-0102-06 | 72237-0102 | selinexor | XPOVIO | 40.0 mg/1 | Chemotherapy | Enzyme Inhibitor | XPO1 | Oral | May 19, 2021 | In Use | |
72237-0102-07 | 72237-0102 | selinexor | XPOVIO | 40.0 mg/1 | Chemotherapy | Enzyme Inhibitor | XPO1 | Oral | May 19, 2021 | In Use | |
00245-0575-01 | 00245-0575 | Isotretinoin | Isotretinoin | 40.0 mg/1 | Hormonal Therapy | Immunomodulator | Retinoic Acid Derivative | Oral | June 25, 2021 | In Use | |
71335-2181-01 | 71335-2181 | Megestrol Acetate | Megestrol Acetate | 40.0 mg/1 | Hormonal Therapy | Progestin Analog | Oral | Oct. 25, 2022 | In Use | ||
71335-2181-02 | 71335-2181 | Megestrol Acetate | Megestrol Acetate | 40.0 mg/1 | Hormonal Therapy | Progestin Analog | Oral | Oct. 25, 2022 | In Use | ||
71335-2181-03 | 71335-2181 | Megestrol Acetate | Megestrol Acetate | 40.0 mg/1 | Hormonal Therapy | Progestin Analog | Oral | Oct. 25, 2022 | In Use | ||
58181-3041-05 | 58181-3041 | Lomustine | Gleostine | 40.0 mg/1 | Chemotherapy | Alkylating Agent | Nitrosourea | Oral | Aug. 18, 2014 | In Use | |
00143-9753-25 | 00143-9753 | Methylprednisolone Sodium Succinate | Methylprednisolone Sodium Succinate | 40.0 mg/1 | Hormonal Therapy | Adrenal Glucocorticoid | Corticosteroid | Intramuscular, Intravenous | Sept. 26, 2022 | In Use | |
42388-0025-26 | 42388-0025 | Cabozantinib | CABOMETYX | 40.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | VEGFR | Oral | April 25, 2016 | In Use | |
42388-0025-37 | 42388-0025 | Cabozantinib | CABOMETYX | 40.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | VEGFR | Oral | Feb. 27, 2019 | In Use | |
42388-0025-46 | 42388-0025 | Cabozantinib | CABOMETYX | 40.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | VEGFR | Oral | Jan. 9, 2023 | In Use | |
42388-0025-57 | 42388-0025 | Cabozantinib | CABOMETYX | 40.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | VEGFR | Oral | Jan. 9, 2023 | In Use | |
49884-0290-01 | 49884-0290 | Megestrol Acetate | Megestrol Acetate | 40.0 mg/1 | Hormonal Therapy | Progestin Analog | Oral | Aug. 8, 1988 | Dec. 31, 2024 | In Use | |
49884-0290-04 | 49884-0290 | Megestrol Acetate | Megestrol Acetate | 40.0 mg/1 | Hormonal Therapy | Progestin Analog | Oral | Aug. 8, 1988 | Sept. 30, 2024 | In Use | |
49884-0290-05 | 49884-0290 | Megestrol Acetate | Megestrol Acetate | 40.0 mg/1 | Hormonal Therapy | Progestin Analog | Oral | Aug. 8, 1988 | Dec. 31, 2024 | In Use | |
80725-0630-25 | 80725-0630 | Thioguanine | TABLOID | 40.0 mg/1 | Chemotherapy | Antimetabolite | Purine Analog | Oral | May 15, 2023 | In Use | |
00378-6614-85 | 00378-6614 | Isotretinoin | Amnesteem | 40.0 mg/1 | Hormonal Therapy | Immunomodulator | Retinoic Acid Derivative | Oral | Sept. 11, 2015 | In Use | |
00378-6614-88 | 00378-6614 | Isotretinoin | Amnesteem | 40.0 mg/1 | Hormonal Therapy | Immunomodulator | Retinoic Acid Derivative | Oral | Nov. 11, 2002 | July 24, 2013 | In Use |
00378-6614-93 | 00378-6614 | Isotretinoin | Amnesteem | 40.0 mg/1 | Hormonal Therapy | Immunomodulator | Retinoic Acid Derivative | Oral | Nov. 11, 2002 | In Use | |
00469-1425-21 | 00469-1425 | Gilteritinib | Xospata | 40.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | FLT3 | Oral | April 30, 2022 | In Use | |
00469-1425-90 | 00469-1425 | Gilteritinib | Xospata | 40.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | FLT3 | Oral | Nov. 29, 2018 | In Use | |
00469-1725-56 | 00469-1725 | Enzalutamide | Xtandi | 40.0 mg/1 | Hormonal Therapy | Androgen Receptor Inhibitor | Non-Steroidal | Oral | Aug. 4, 2020 | In Use | |
00904-7236-61 | 00904-7236 | Megestrol Acetate | Megestrol Acetate | 40.0 mg/1 | Hormonal Therapy | Progestin Analog | Oral | June 1, 2022 | In Use | ||
69784-0630-25 | 69784-0630 | Thioguanine | TABLOID | 40.0 mg/1 | Chemotherapy | Antimetabolite | Purine Analog | Oral | June 30, 2022 | In Use | |
76388-0880-25 | 76388-0880 | Thioguanine | Tabloid | 40.0 mg/1 | Chemotherapy | Antimetabolite | Purine Analog | Oral | March 12, 2013 | March 31, 2025 | In Use |
00143-9136-01 | 00143-9136 | Mitomycin | Mitomycin | 40.0 mg/1 | Chemotherapy | Antitumor Antibiotic | Alkylating Agent/ Mitomycin | Intravenous | Oct. 1, 2022 | In Use | |
64380-0159-01 | 64380-0159 | Megestrol Acetate | Megestrol Acetate | 40.0 mg/1 | Hormonal Therapy | Progestin Analog | Oral | April 4, 2022 | In Use | ||
64380-0159-03 | 64380-0159 | Megestrol Acetate | Megestrol Acetate | 40.0 mg/1 | Hormonal Therapy | Progestin Analog | Oral | April 4, 2022 | In Use | ||
64380-0159-02 | 64380-0159 | Megestrol Acetate | Megestrol Acetate | 40.0 mg/1 | Hormonal Therapy | Progestin Analog | Oral | April 4, 2022 | In Use | ||
72143-0254-30 | 72143-0254 | ISOTRETINOIN | ACCUTANE | 40.0 mg/1 | Hormonal Therapy | Immunomodulator | Retinoic Acid Derivative | Oral | Aug. 1, 2022 | In Use | |
13668-0591-81 | 13668-0591 | APREPITANT | APREPITANT | 40.0 mg/1 | Ancillary Therapy | Antiemetic | Substance P/Neurokinin 1 | Oral | Oct. 21, 2020 | In Use | |
13668-0591-82 | 13668-0591 | APREPITANT | APREPITANT | 40.0 mg/1 | Ancillary Therapy | Antiemetic | Substance P/Neurokinin 1 | Oral | Oct. 21, 2020 | In Use | |
42254-0160-01 | 42254-0160 | Aprepitant | Emend | 40.0 mg/1 | Ancillary Therapy | Antiemetic | Substance P/Neurokinin 1 | Oral | March 26, 2003 | In Use | |
57664-0025-97 | 57664-0025 | Isotretinoin | Isotretinoin | 40.0 mg/1 | Hormonal Therapy | Immunomodulator | Retinoic Acid Derivative | Oral | Dec. 29, 2020 | In Use | |
61748-0304-01 | 61748-0304 | Isotretinoin | Myorisan | 40.0 mg/1 | Hormonal Therapy | Immunomodulator | Retinoic Acid Derivative | Oral | May 1, 2012 | In Use | |
61748-0304-11 | 61748-0304 | Isotretinoin | Myorisan | 40.0 mg/1 | Hormonal Therapy | Immunomodulator | Retinoic Acid Derivative | Oral | May 1, 2012 | In Use | |
61748-0304-13 | 61748-0304 | Isotretinoin | Myorisan | 40.0 mg/1 | Hormonal Therapy | Immunomodulator | Retinoic Acid Derivative | Oral | May 1, 2012 | In Use | |
72143-0234-30 | 72143-0234 | ISOTRETINOIN | ACCUTANE | 40.0 mg/1 | Hormonal Therapy | Immunomodulator | Retinoic Acid Derivative | Oral | Jan. 11, 2021 | Dec. 31, 2023 | No Longer Used |
70437-0240-18 | 70437-0240 | Neratinib | Nerlynx | 40.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | EGFR/HER2 | Oral | July 17, 2017 | In Use | |
70437-0240-26 | 70437-0240 | Neratinib | Nerlynx | 40.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | EGFR/HER2 | Oral | July 17, 2017 | In Use | |
70437-0240-33 | 70437-0240 | Neratinib | Nerlynx | 40.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | EGFR/HER2 | Oral | July 17, 2017 | In Use | |
60429-0433-01 | 60429-0433 | Megestrol Acetate | Megestrol Acetate | 40.0 mg/1 | Hormonal Therapy | Progestin Analog | Oral | Sept. 4, 2015 | Dec. 31, 2024 | In Use | |
60429-0433-05 | 60429-0433 | Megestrol Acetate | Megestrol Acetate | 40.0 mg/1 | Hormonal Therapy | Progestin Analog | Oral | Sept. 4, 2015 | March 31, 2024 | In Use | |
00006-5331-01 | 00006-5331 | Belzutifan | WELIREG | 40.0 mg/1 | Chemotherapy | Miscellaneous Agent | HIF-2 alpha | Oral | Aug. 13, 2021 | In Use | |
00006-5331-58 | 00006-5331 | Belzutifan | WELIREG | 40.0 mg/1 | Chemotherapy | Miscellaneous Agent | HIF-2 alpha | Oral | June 21, 2023 | In Use | |
00006-5331-59 | 00006-5331 | Belzutifan | WELIREG | 40.0 mg/1 | Chemotherapy | Miscellaneous Agent | HIF-2 alpha | Oral | June 21, 2023 | In Use | |
00904-3571-61 | 00904-3571 | Megestrol Acetate | Megestrol Acetate | 40.0 mg/1 | Hormonal Therapy | Progestin Analog | Oral | Feb. 16, 2004 | July 31, 2023 | No Longer Used | |
70710-1025-04 | 70710-1025 | Isotretinoin | Isotretinoin | 40.0 mg/1 | Hormonal Therapy | Immunomodulator | Retinoic Acid Derivative | Oral | Sept. 12, 2023 | In Use | |
70710-1025-08 | 70710-1025 | Isotretinoin | Isotretinoin | 40.0 mg/1 | Hormonal Therapy | Immunomodulator | Retinoic Acid Derivative | Oral | Sept. 12, 2023 | In Use | |
70771-1560-04 | 70771-1560 | Isotretinoin | Isotretinoin | 40.0 mg/1 | Hormonal Therapy | Immunomodulator | Retinoic Acid Derivative | Oral | Sept. 12, 2023 | In Use | |
70771-1560-08 | 70771-1560 | Isotretinoin | Isotretinoin | 40.0 mg/1 | Hormonal Therapy | Immunomodulator | Retinoic Acid Derivative | Oral | Sept. 12, 2023 | In Use | |
59651-0636-03 | 59651-0636 | ISOTRETINOIN | ISOTRETINOIN | 40.0 mg/1 | Hormonal Therapy | Immunomodulator | Retinoic Acid Derivative | Oral | Jan. 29, 2024 | In Use | |
00003-4040-12 | 00003-4040 | Repotrectinib | Augtyro | 40.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | ROS1, TRKA, TRKB, TRKC | Oral | Dec. 5, 2023 | In Use | |
00003-4040-60 | 00003-4040 | Repotrectinib | Augtyro | 40.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | ROS1, TRKA, TRKB, TRKC | Oral | Dec. 5, 2023 | In Use | |
73042-0201-01 | 73042-0201 | Naxitamab | DANYELZA | 40.0 mg/10mL | Immunotherapy | Monoclonal Antibody | GD2 | Intravenous | Nov. 25, 2020 | In Use | |
16729-0248-38 | 16729-0248 | Mitomycin | Mitomycin | 40.0 mg/10mL | Chemotherapy | Antitumor Antibiotic | Alkylating Agent/ Mitomycin | Intravenous | May 3, 2013 | Jan. 31, 2023 | No Longer Used |
00703-4432-11 | 00703-4432 | Irinotecan Hydrochloride | Irinotecan Hydrochloride | 40.0 mg/2mL | Chemotherapy | Topoisomerase I Inhibitor | Camptothecin Analogs | Intravenous | Feb. 28, 2008 | Nov. 30, 2019 | No Longer Used |
00703-4432-81 | 00703-4432 | Irinotecan Hydrochloride | Irinotecan Hydrochloride | 40.0 mg/2mL | Chemotherapy | Topoisomerase I Inhibitor | Camptothecin Analogs | Intravenous | July 1, 2015 | July 31, 2019 | No Longer Used |
47335-0937-40 | 47335-0937 | Irinotecan Hydrochloride | Irinotecan Hydrochloride | 40.0 mg/2mL | Chemotherapy | Topoisomerase I Inhibitor | Camptothecin Analogs | Intravenous | April 21, 2008 | Jan. 24, 2017 | No Longer Used |
50742-0401-02 | 50742-0401 | Irinotecan Hydrochloride | Irinotecan Hydrochloride | 40.0 mg/2mL | Chemotherapy | Topoisomerase I Inhibitor | Camptothecin Analogs | Intravenous | June 5, 2017 | In Use | |
65219-0552-02 | 65219-0552 | Pralatrexate | Pralatrexate | 40.0 mg/2mL | Chemotherapy | Antimetabolite | Folic Acid Analog | Intravenous | Nov. 15, 2022 | In Use | |
51144-0003-01 | 51144-0003 | Tisotumab vedotin | TIVDAK | 40.0 mg/4mL | Immunotherapy | Drug Antibody Conjugate | Tissue factor | Intravenous | Sept. 20, 2021 | In Use | |
16729-0116-38 | 16729-0116 | Mitomycin | Mitomycin | 40.0 mg/80mL | Chemotherapy | Antitumor Antibiotic | Alkylating Agent/ Mitomycin | Intravenous | March 11, 2011 | In Use | |
69448-0003-38 | 69448-0003 | Mitomycin | Mutamycin | 40.0 mg/80mL | Chemotherapy | Antitumor Antibiotic | Alkylating Agent/ Mitomycin | Intravenous | July 25, 2017 | In Use | |
68001-0391-79 | 68001-0391 | Mitomycin | Mitomycin | 40.0 mg/80mL | Chemotherapy | Antitumor Antibiotic | Alkylating Agent/ Mitomycin | Intravenous | May 14, 2019 | In Use | |
68083-0502-01 | 68083-0502 | MITOMYCIN | MITOMYCIN | 40.0 mg/80mL | Chemotherapy | Antitumor Antibiotic | Alkylating Agent/ Mitomycin | Intravenous | Nov. 22, 2022 | In Use | |
65219-0568-00 | 65219-0568 | MITOMYCIN | MITOMYCIN | 40.0 mg/80mL | Chemotherapy | Antitumor Antibiotic | Alkylating Agent/ Mitomycin | Intravenous | Jan. 15, 2023 | In Use | |
72819-0154-04 | 72819-0154 | Mitomycin | Mitomycin | 40.0 mg/80mL | Chemotherapy | Antitumor Antibiotic | Alkylating Agent/ Mitomycin | Intravenous | April 25, 2022 | In Use | |
71288-0139-51 | 71288-0139 | MITOMYCIN | MITOMYCIN | 40.0 mg/80mL | Chemotherapy | Antitumor Antibiotic | Alkylating Agent/ Mitomycin | Intravenous | Sept. 6, 2022 | In Use | |
55150-0452-01 | 55150-0452 | MITOMYCIN | MITOMYCIN | 40.0 mg/80mL | Chemotherapy | Antitumor Antibiotic | Alkylating Agent/ Mitomycin | Intravenous | Oct. 30, 2023 | In Use | |
67457-0520-40 | 67457-0520 | Mitomycin | Mitomycin | 40.0 mg/80mL | Chemotherapy | Antitumor Antibiotic | Alkylating Agent/ Mitomycin | Intravenous | March 19, 2018 | In Use | |
67457-0997-40 | 67457-0997 | Mitomycin | Mitomycin | 40.0 mg/80mL | Chemotherapy | Antitumor Antibiotic | Alkylating Agent/ Mitomycin | Intravenous | Aug. 28, 2020 | In Use | |
25021-0252-51 | 25021-0252 | Mitomycin | Mitomycin | 40.0 mg/80mL | Chemotherapy | Antitumor Antibiotic | Alkylating Agent/ Mitomycin | Intravenous | June 15, 2023 | In Use | |
42023-0112-01 | 42023-0112 | Estradiol Valerate | Delestrogen | 40.0 mg/mL | Hormonal Therapy | Estrogen | Intramuscular | Nov. 1, 2007 | In Use | ||
55390-0391-10 | 55390-0391 | Gemcitabine Hydrochloride | Gemcitabine Hydrochloride | 40.0 mg/mL | Chemotherapy | Antimetabolite | Pyrimidine Analog | Intravenous | March 19, 2012 | In Use | |
55390-0391-50 | 55390-0391 | Gemcitabine Hydrochloride | Gemcitabine Hydrochloride | 40.0 mg/mL | Chemotherapy | Antimetabolite | Pyrimidine Analog | Intravenous | March 19, 2012 | In Use | |
54868-0590-00 | 54868-0590 | Methylprednisolone Acetate | Methylprednisolone Acetate | 40.0 mg/mL | Hormonal Therapy | Adrenal Glucocorticoid | Corticosteroid | Intramuscular, Soft Tissue, Intrasynovial | July 26, 2012 | In Use | |
55154-3929-05 | 55154-3929 | Methylprednisolone Acetate | Depo-Medrol | 40.0 mg/mL | Hormonal Therapy | Adrenal Glucocorticoid | Corticosteroid | Intra-articular, Intralesional, Intramuscular, Soft Tissue | May 28, 1959 | In Use | |
55154-3914-05 | 55154-3914 | Methylprednisolone Sodium Succinate | Solu-Medrol | 40.0 mg/mL | Hormonal Therapy | Adrenal Glucocorticoid | Corticosteroid | Intramuscular, Intravenous | April 2, 1959 | June 30, 2010 | No Longer Used |
55154-3939-05 | 55154-3939 | Methylprednisolone Sodium Succinate | Solu-Medrol | 40.0 mg/mL | Hormonal Therapy | Adrenal Glucocorticoid | Corticosteroid | Intramuscular, Intravenous | April 2, 1959 | In Use | |
55154-9383-05 | 55154-9383 | Methylprednisolone Sodium Succinate | Methylprednisolone Sodium Succinate | 40.0 mg/mL | Hormonal Therapy | Adrenal Glucocorticoid | Corticosteroid | Intramuscular, Intravenous | Nov. 30, 2004 | In Use | |
63323-0255-03 | 63323-0255 | Methylprednisolone Sodium Succinate | Methylprednisolone Sodium Succinate | 40.0 mg/mL | Hormonal Therapy | Adrenal Glucocorticoid | Corticosteroid | Intramuscular, Intravenous | Nov. 30, 2004 | In Use | |
00409-3217-05 | 00409-3217 | Methylprednisolone Sodium Succinate | A-Methapred | 40.0 mg/mL | Hormonal Therapy | Adrenal Glucocorticoid | Corticosteroid | Intramuscular, Intravenous | Oct. 6, 2006 | July 1, 2010 | No Longer Used |
00409-3217-15 | 00409-3217 | Methylprednisolone Sodium Succinate | A-Methapred | 40.0 mg/mL | Hormonal Therapy | Adrenal Glucocorticoid | Corticosteroid | Intramuscular, Intravenous | Oct. 6, 2006 | July 1, 2010 | No Longer Used |
00143-9291-01 | 00143-9291 | Estradiol Valerate | Estradiol Valerate | 40.0 mg/mL | Hormonal Therapy | Estrogen | Intramuscular | April 21, 2020 | In Use | ||
00517-0440-01 | 00517-0440 | ESTRADIOL VALERATE | ESTRADIOL VALERATE | 40.0 mg/mL | Hormonal Therapy | Estrogen | Intramuscular | March 1, 2020 | In Use | ||
00703-0241-01 | 00703-0241 | Triamcinolone Acetonide | Triamcinolone Acetonide | 40.0 mg/mL | Hormonal Therapy | Adrenal Glucocorticoid | Corticosteroid | Intra-articular, Intramuscular | Aug. 29, 2019 | In Use |
Found 10,000 results in 18 milliseconds — Export these results